Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 1/20 | 0.37 |
| ▸ | NAMPT | P43490 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | BLM | P54132 | 1/20 | 0.33 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.31 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.31 |
| ▸ | LIPA | P38571 | 1/20 | 0.31 |
| ▸ | APLNR | P35414 | 1/20 | 0.30 |
| ▸ | IDO1 | P14902 | 1/20 | 0.30 |
| ▸ | TDO2 | P48775 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16350871 | 0.84 | ESR2 (0.33) | NAMPTAKR1C3FFAR4LIPA | |
| SCHEMBL30507548 | 0.84 | NAMPT (0.35) | EPHX2NAMPTLMNABLMFFAR4 | |
| SCHEMBL939927 | 0.82 | FFAR4 (0.44) | LMNABLMFFAR4 | |
| SCHEMBL6273456 | 0.80 | LMNA (0.36) | EPHX2NAMPTLMNABLMFFAR4 | |
| SCHEMBL15116404 | 0.80 | EPHX2 (0.39) | EPHX2NAMPTAKR1C3FFAR4LIPA | |
| SCHEMBL15043693 | 0.80 | LIPA (0.38) | NAMPTLMNAAKR1C3LIPA | |
| SCHEMBL14576723 | 0.80 | LIPA (0.38) | NAMPTLMNAAKR1C3LIPA | |
| SCHEMBL526891 | 0.80 | — | — | |
| SCHEMBL14306150 | 0.78 | TDP1 (0.36) | EPHX2NAMPTLMNABLMFFAR4 | |
| Hydrochloric Acid SCHEMBL29904545 | 0.78 | LMNA (0.35) | EPHX2NAMPTLMNABLM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8563742-B2 | Substituted aminothiazole derivatives, pharmaceutical compositions, and methods of use | HIGH POINT PHARMACEUTICALS, LLC (US) | 2013-10-22 | — | — | US | disclosed |
| EP-2320738-A1 | SUBSTITUTED AMINOTHIAZOLE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE | TransTech Pharma, Inc. (US) | 2011-05-18 | — | — | EP | disclosed |
| US-20100056587-A1 | Substituted Aminothiazole Derivatives, Pharmaceutical Compositions, And Methods Of Use | VTVX HOLDINGS I LLC | 2010-03-04 | — | — | US | disclosed |
| WO-2010025142-A1 | SUBSTITUTED AMINOTHIAZOLE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE | TRANSTECH PHARMA, INC. (US) | 2010-03-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100056587-A1 | Substituted Aminothiazole Derivatives, Pharmaceutical Compositions, And Methods Of Use | MC4R, MC3R, MC5R | EPHX2 4761/4885NAMPT 152/4885LMNA 4558/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.